secwatch.observer — SEC 8-K summary
======================================

Issuer:     Elicio Therapeutics, Inc. (ELTX)
CIK:        0001601485
Form:       8-K
Filed at:   2026-03-12T23:59:59+00:00
Accession:  0001601485-26-000026
Event type: earnings
Sentiment:  positive
Materiality: 0.75
Item codes: 2.02, 9.01
LLM model:  deepseek-v4-flash:cloud@v2

Elicio Therapeutics reports FY2025 net loss of $39.5M; Phase 2 PDAC trial DFS readout expected 1H 2026
--------------------------------------------------------------------------------

- Net loss for 2025 was $39.5M ($2.58 per share), compared to $51.9M ($4.25) in 2024.
- R&D expense decreased to $24.9M from $33.7M; G&A expense increased to $12.8M from $11.3M.
- Cash and equivalents $18.6M as of Dec 31, 2025; runway into Q3 2026 beyond expected Phase 2 DFS analysis.
- Phase 2 AMPLIFY-7P trial in PDAC: fewer progressions and deaths observed than projected; primary DFS analysis on track for 1H 2026.
- Raised net ~$4.9M in Q4 2025 and ~$6.3M in Q1 2026 via at-the-market program; appointed Marc J. Wolfgang as CTO.

Source:
  EDGAR index:    https://www.sec.gov/Archives/edgar/data/1601485/000160148526000026/0001601485-26-000026-index.htm
  Primary doc:    https://www.sec.gov/Archives/edgar/data/1601485/000160148526000026/angn-20260312.htm
  HTML page:      https://secwatch.observer/filing/0001601485-26-000026

License: Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer